{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T15:51:42Z","timestamp":1777650702040,"version":"3.51.4"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,7,16]],"date-time":"2020-07-16T00:00:00Z","timestamp":1594857600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,7,16]],"date-time":"2020-07-16T00:00:00Z","timestamp":1594857600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>Hepatitis E virus (HEV) may be resistant to immunosuppression reduction and ribavirin treatment in kidney transplant recipients because of mutant strains and severe side effects of ribavirin which conduct to dose reduction. Sofosbuvir efficacy is controversial. Peg-interferon 2 alpha (PEG-IFN) is currently contraindicated due to a high risk of acute humoral and cellular rejection. The present study assessed, for the first time, the effect of PEG-IFN in a kidney transplant recipient infected with HEV.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Case presentation<\/jats:title>\n<jats:p>The patient had chronic active HEV that was resistant to immunosuppression reduction and optimal ribavirin treatment. He developed significant liver fibrosis. PEG-IFN was administered for 10\u2009months, and it was well tolerated and did not induce rejection. A sustained virological response was obtained.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusions<\/jats:title>\n<jats:p>We conclude that prolonged treatment with PEG-IFN in kidney transplant recipients infected with HEV could be considered as a salvage option.<\/jats:p>\n<\/jats:sec>","DOI":"10.1186\/s12879-020-05212-2","type":"journal-article","created":{"date-parts":[[2020,7,16]],"date-time":"2020-07-16T17:02:36Z","timestamp":1594918956000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Pegylated interferon may be considered in chronic viral hepatitis E resistant to ribavirin in kidney transplant recipients"],"prefix":"10.1186","volume":"20","author":[{"given":"I.","family":"Ollivier-Hourmand","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0218-5542","authenticated-orcid":false,"given":"L.","family":"Lebedel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Lecouf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Allaire","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T. T. N.","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Lier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Dao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,7,16]]},"reference":[{"key":"5212_CR1","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1016\/j.jhep.2018.03.005","volume":"68","author":"European Association for the Study of the Liver","year":"2018","unstructured":"European Association for the Study of the Liver. EASL clinical practice guidelines on hepatitis E virus infection. J Hepatol. 2018;68:1256\u201371.","journal-title":"J Hepatol"},{"key":"5212_CR2","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1097\/MOG.0b013e32835ff238","volume":"29","author":"N Kamar","year":"2013","unstructured":"Kamar N, Izopet J, Rostaing L. Hepatitis E virus infection. Curr Opin Gastroenterol. 2013;29:271\u20138.","journal-title":"Curr Opin Gastroenterol"},{"key":"5212_CR3","doi-asserted-by":"publisher","first-page":"125","DOI":"10.3851\/IMP2705","volume":"19","author":"Z Abbas","year":"2014","unstructured":"Abbas Z, Afzal R. Hepatitis E: when to treat and how to treat. Antivir Ther. 2014;19:125\u201331.","journal-title":"Antivir Ther"},{"key":"5212_CR4","doi-asserted-by":"publisher","first-page":"e13514","DOI":"10.1111\/ctr.13514","volume":"33","author":"H Te","year":"2019","unstructured":"Te H, Doucette K. Viral hepatitis: guidelines by the American society of transplantation infectious disease community of practice. Clin Transpl. 2019;33:e13514.","journal-title":"Clin Transpl"},{"key":"5212_CR5","doi-asserted-by":"publisher","first-page":"211","DOI":"10.3390\/v8080211","volume":"8","author":"J Hartl","year":"2016","unstructured":"Hartl J, Otto B, Madden RG, Webb G, Woolson KL, Kriston L, et al. Hepatitis E seroprevalence in Europe: a meta-analysis. Viruses. 2016;8:211.","journal-title":"Viruses"},{"key":"5212_CR6","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/j.jhep.2016.05.002","volume":"65","author":"Y Debing","year":"2016","unstructured":"Debing Y, Rami\u00e8re C, Dallmeier K, Piorkowski G, Trabaud MA, Leboss\u00e9 F, et al. Hepatitis E virus mutations associated with ribavirin treatment failure result in altered viral fitness and ribavirin sensitivity. J Hepatol. 2016;65:499\u2013508.","journal-title":"J Hepatol"},{"key":"5212_CR7","doi-asserted-by":"publisher","first-page":"1608","DOI":"10.1128\/AAC.02496-15","volume":"60","author":"S Lhomme","year":"2015","unstructured":"Lhomme S, Kamar N, Nicot F, Ducos J, Bismuth M, Garrigue V, et al. Mutation in the hepatitis E virus polymerase and outcome of ribavirin therapy. Antimicrob Agents Chemother. 2015;60:1608\u201314.","journal-title":"Antimicrob Agents Chemother"},{"key":"5212_CR8","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.clinre.2018.09.010","volume":"43","author":"L Luciani","year":"2019","unstructured":"Luciani L, Deharo P, Aherfi S, Chalvignac V, Borentain P, Colson P. Hepatitis E virus infection in heart transplant recipients, Southeastern France. Clin Res Hepatol Gastroenterol. 2019;43:108\u201311.","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"5212_CR9","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1053\/j.gastro.2016.05.060","volume":"152","author":"MC Donnelly","year":"2017","unstructured":"Donnelly MC, Imlach SN, Abravanel F, Ramalingam S, Johannessen I, Petrik J, et al. Sofosbuvir and daclatasvir anti-viral therapy fails to clear HEV viremia and restore reactive T cells in a HEV\/HCV co-infected liver transplant recipient. Gastroenterology. 2017;152:300\u20131.","journal-title":"Gastroenterology"},{"key":"5212_CR10","doi-asserted-by":"publisher","first-page":"2297","DOI":"10.1002\/hep.30428","volume":"69","author":"M Drinane","year":"2019","unstructured":"Drinane M, Jing Wang X, Watt K. Sofosbuvir and ribavirin eradication of refractory hepatitis E in an immunosuppressed kidney transplant recipient. Hepatology. 2019;69:2297\u20139.","journal-title":"Hepatology"},{"key":"5212_CR11","doi-asserted-by":"publisher","first-page":"1846","DOI":"10.1002\/hep.30546","volume":"69","author":"N Kamar","year":"2019","unstructured":"Kamar N, Pan Q. No clear evidence for an effect of sofosbuvir against hepatitis E virus in organ transplant patients. Hepatology. 2019;69:1846\u20137.","journal-title":"Hepatology"},{"key":"5212_CR12","doi-asserted-by":"publisher","first-page":"463","DOI":"10.3851\/IMP3227","volume":"23","author":"E Todesco","year":"2018","unstructured":"Todesco E, Mazzola A, Akhavan S, Abravanel F, Poynard T, Roque-Afonso AM, et al. Chronic hepatitis E in a heart transplant patient: sofosbuvir and ribavirin regimen not fully effective. Antivir Ther. 2018;23:463\u20135.","journal-title":"Antivir Ther"},{"key":"5212_CR13","doi-asserted-by":"publisher","first-page":"e30","DOI":"10.1086\/650488","volume":"50","author":"N Kamar","year":"2010","unstructured":"Kamar N, Rostaing L, Abravanel F, Garrouste C, Esposito L, Cardeau-Desangles I, et al. Pegylated interferon-alpha for treating chronic hepatitis E virus infection after liver transplantation. Clin Infect Dis. 2010;50:e30\u20133.","journal-title":"Clin Infect Dis"},{"key":"5212_CR14","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1002\/lt.21926","volume":"16","author":"EB Haagsma","year":"2010","unstructured":"Haagsma EB, Riezebos-Brilman A, van den Berg AP, Porte RJ, Niesters HG. Treatment of chronic hepatitis E in liver transplant recipients with pegylated interferon alpha-2b. Liver Transpl. 2010;16:474\u20137.","journal-title":"Liver Transpl"},{"key":"5212_CR15","doi-asserted-by":"publisher","first-page":"1634","DOI":"10.1016\/j.transproceed.2017.05.006","volume":"49","author":"R Nakano","year":"2017","unstructured":"Nakano R, Ohira M, Ishiyama K, Ide K, Kobayashi T, Tahara H, et al. Acute graft rejection and formation of de novo donor-specific antibodies triggered by low cyclosporine levels and interferon therapy for recurrent hepatitis C infection after liver transplantation: a case report. Transplant Proc. 2017;49:1634\u20138.","journal-title":"Transplant Proc"},{"key":"5212_CR16","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.jhep.2010.11.012","volume":"55","author":"N Selzner","year":"2011","unstructured":"Selzner N, Guindi M, Renner EL, Berenguer M. Immune-mediated complications of the graft in interferon-treated hepatitis C positive liver transplant recipients. J Hepatol. 2011;55:207\u201317.","journal-title":"J Hepatol"},{"issue":"1","key":"5212_CR17","doi-asserted-by":"publisher","first-page":"110","DOI":"10.3201\/eid1501.080296","volume":"15","author":"F Legrand-Abravanel","year":"2009","unstructured":"Legrand-Abravanel F, Mansuy JM, Dubois M, et al. Hepatitis E virus genotype 3 diversity, France. Emerg Infect Dis. 2009;15(1):110\u20134.","journal-title":"Emerg Infect Dis"},{"key":"5212_CR18","doi-asserted-by":"publisher","unstructured":"Kamar N, Abravanel F, Behrendt P, Hofmann J, Pageaux GP, Barbet C, et al. Ribavirin for hepatitis E virus infection after organ transplantation: a large European retrospective multicenter study. Clin Infect Dis. 2019:ciz953. https:\/\/doi.org\/10.1093\/cid\/ciz953 Epub ahead of print. PMID: 31793638.","DOI":"10.1093\/cid\/ciz953"},{"key":"5212_CR19","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.healun.2012.10.008","volume":"32","author":"L Koning","year":"2013","unstructured":"Koning L, Pas SD, de Man RA, Balk AH, de Knegt RJ, ten Kate FJ, et al. Clinical implications of chronic hepatitis E virus infection in heart transplant recipients. J Heart Lung Transplant. 2013;32:78\u201385.","journal-title":"J Heart Lung Transplant"},{"key":"5212_CR20","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1056\/NEJMc0708687","volume":"358","author":"R G\u00e9rolami","year":"2008","unstructured":"G\u00e9rolami R, Moal V, Colson P. Chronic hepatitis E with cirrhosis in a kidney-transplant recipient. N Engl J Med. 2008;358:859\u201360.","journal-title":"N Engl J Med"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-020-05212-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-020-05212-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-020-05212-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,15]],"date-time":"2021-07-15T23:14:28Z","timestamp":1626390868000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-020-05212-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,16]]},"references-count":20,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["5212"],"URL":"https:\/\/doi.org\/10.1186\/s12879-020-05212-2","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,16]]},"assertion":[{"value":"13 February 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 June 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 July 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor of this journal.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"522"}}